TScan is a clinical-stage biopharmaceutical company advancing a robust pipeline of T cell receptor-engineered T cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
We work with key collaborators, including academic institutions, pharmaceutical companies, and other key partners to advance our programs and discover new opportunities.
While our primary focus is on the development of T cell therapies to treat cancer, T cells play a fundamental role in many other disease areas, such as autoimmune disease and infectious disease. We believe that our proprietary platform technologies are well suited to better understand disease pathology and discover novel antigens for the development of therapeutics, diagnostics, and vaccines in these other areas.
TScan seeks to expand our reach, support greater understanding, and drive therapeutic development in these additional disease areas through collaborations with strategic partners.
For more information, please contact us at firstname.lastname@example.org.
In May 2023, Amgen (NASDAQ: AMGN) and TScan Therapeutics initiated a multi-year collaboration that harnesses TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan and will retain all global development and commercial rights.